Latest Regulatory Delays News

Mayne Pharma’s planned acquisition by Cosette Pharmaceuticals faces a delay as the Foreign Investment Review Board postpones its decision, potentially pushing back key court proceedings.

Health Canada has requested additional information, extending its review of CLINUVEL’s SCENESSE® for erythropoietic protoporphyria (EPP) into 2026. Meanwhile, Canadian patients continue to access the treatment via a Special Access Program.

St Barbara Limited forecasts a 21% increase in gold production for FY26 at its Simberi Operations, with costs expected between A$4,000 and A$4,400 per ounce. However, key capital investment decisions hinge on unresolved Papua New Guinea tax assessments and mining lease approvals.

Elanor Investors Group has obtained a crucial ASX waiver allowing a longer timeframe to issue securities tied to its $125 million recapitalisation with Rockworth Investment. This move addresses regulatory delays and aims to stabilise Elanor's balance sheet and reduce gearing.

Locksley Resources reports robust metallurgical testwork from its Mojave Project, confirming high antimony recoveries and concentrate grades that support a domestic US supply chain. The results align with US strategic priorities for critical mineral independence.

Peak Rare Earths has postponed its critical court hearing for Shenghe Resources' acquisition scheme due to a delay in Tanzanian regulatory approval, pushing the decision to 19 September 2025.

Aguia Resources has updated its economic study for the Tres Estrades Rock Phosphate Project, reflecting a significant uplift in phosphate pricing and expanded production capacity that together enhance the project's financial outlook.

Hartshead Resources has struck a pivotal Well Carry Agreement with RockRose Energy, securing full funding for its Phase C drilling costs while trimming its joint venture stake. The move also triggers a licence extension application amid UK regulatory delays.

MEC Resources Ltd has reported a net profit of $207,490 for the 2025 financial year, reversing prior losses, while advancing a significant legal challenge through its investee Advent Energy Ltd and raising $2.6 million via an entitlement offer.

Reef Casino Trust and Iris Cairns Property Pty Ltd have agreed to increase the takeover bid price to $3.87 per unit, boosting the total offer value to approximately A$192.7 million. The unanimous board recommendation and major unitholder support underscore the deal’s momentum amid regulatory conditions.

Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.

Australian Unity Limited reported robust FY2025 financial results, driven by strategic acquisitions and ongoing transformation efforts, returning to profitability with a $26.6 million net profit. The company is poised to complete its multi-year transformation by year-end and focus on growth amid rising demand for aged care and health services.